{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-092871","form_type":"8-K","ticker":"NVCT","cik":"0001875558","company_name":"Nuvectis Pharma, Inc.","filed_at":"2023-08-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.959101+00:00","generated_at":"2026-06-11T08:01:27.333088+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Nuvectis Pharma gets FDA Orphan Drug Designation for NXP800 in cholangiocarcinoma","bullets":["FDA granted Orphan Drug Designation to NXP800 for cholangiocarcinoma.","NXP800 is an oral small molecule targeting ARID1a-mutated cancers.","Phase 1b trial ongoing in ARID1a-mutated ovarian carcinoma; cholangiocarcinoma expansion planned.","CEO Ron Bentsur cites unmet medical need in cholangiocarcinoma."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-092871","json":"https://secwatch.observer/filing/0001104659-23-092871.json","markdown":"https://secwatch.observer/filing/0001104659-23-092871.md","text":"https://secwatch.observer/filing/0001104659-23-092871.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1875558/000110465923092871/0001104659-23-092871-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1875558/000110465923092871/tm2323981d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T08:01:27.333088+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}